


**AMENDED CLAIMS**

1-10. (Canceled)

11. (Currently amended) A parenteral pharmaceutical composition with injection site toleration comprising a therapeutically effective amount of an ~~Active Pharmaceutical Ingredient~~, a compound of Formula (Ia).



or a pharmaceutically acceptable salt thereof, a  $\beta$ -cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.

12. (Canceled)

13. (Currently amended) The pharmaceutical composition according to Claim [[12]] 11 wherein the  $\beta$ -cyclodextrin is 2-hydroxypropyl- $\beta$ -cyclodextrin or sulfobutyl ether- $\beta$ -cyclodextrin.

14. (Currently amended) The pharmaceutical composition according to claim [[12]]  
13 wherein the preservative is selected from thimerosal, propylene glycol, phenol, or  
meta-cresol ~~or a combination thereof~~.

15. (Currently amended) The pharmaceutical composition according to claim 14  
wherein the preservative is about 2.5 to about 3.5 mg/mL of meta-cresol, the cyclodextrin  
is sulfobutyl ether- $\beta$ -cyclodextrin, and wherein the pharmaceutically acceptable salt is the  
citrate monohydrate salt.

16. (Currently amended) The pharmaceutical composition according to claim 14  
wherein the preservative has a binding value to the cyclodextrin that is less than [[a]] the  
binding value of the Active Pharmaceutical Ingredient compound of Formula (1a) to  
cyclodextrin.

17-18. (Canceled)

19. (Currently amended) The pharmaceutical composition according to claim 16  
wherein the binding value of the ~~Active Pharmaceutical Ingredient~~ compound of Formula  
(1a) to cyclodextrin is between 800 M<sup>-1</sup> and 31,000 3,000 M<sup>-1</sup>.

20-28. (Canceled)

28. 29. (New) A pharmaceutical composition comprising about 10 mg/mL of a compound  
of Formula (1a), about 3.3 mg/mL meta-cresol, about 63 mg/mL sulfobutyl ether- $\beta$ -  
cyclodextrin, and a pharmaceutically acceptable vehicle.

29. 30. (New) A method for the treatment of emesis in an animal comprising  
administering to said animal a composition according to Claim 11.